December 18, 2008 — AngioDynamics Inc. announced the use of its irreversible electroporation (IRE) technology on a lymph node metastasis and the first lung lesion case at The Alfred in Melbourne, Australia.

Using the NanoKnife system, Ken Thomson, M.D., professor and director of the department of radiology at The Alfred, Monash University, performed the procedures, which were judged by The Alfred to be successful from a safety perspective. The hospital will conduct further patient follow-up before determining final outcomes in terms of tumor response.

Dr. Thomson reported that the two patients who were treated did not report pain related to the procedures. These are the fifth and sixth cases using NanoKnife at The Alfred, with three liver cases and a kidney case preceding them, all with procedural success.

“I have been an interventional radiologist since 1974 and this is the most exciting development in minimal access therapy I have seen,” said Dr. Thomson. “For the patient, the absence of post-operative pain is unique and remarkable. We have also treated tumors in the liver and kidney with NanoKnife, with similar experiences – no postoperative pain at all – and the procedures have raised no safety concerns. This is probably due to the fact that the supporting structure of the tissue treated is not destroyed and vascular and nerve function is unaffected.”

Regarding a previously announced liver case from The Alfred, sequential triple-phase liver CT scans and ultrasound at two weeks and four weeks post-procedure have shown that a 2 cm tumor has disappeared on imaging. At the site of a 3.5 cm tumor near the diaphragm in the same patient there is only a minor non-enhancing scar. Dr Thomson noted these outcomes contrast very favorably with the cavities left following thermal ablation procedures.

NanoKnife causes cell death by impacting the cell membranes of targeted tissue with pulses of electricity, effectively sparing nearby nerves, blood vessels, lymphatic system, and other delicate structures. Targeted cells are removed from the body through blood vessels and lymphatic systems.

This is different from thermal ablation modalities like cryo-ablation, microwave, and radiofrequency ablation. These other modalities destroy all cells including critical structures in targeted tissue, leaving destroyed material in place for years. The body can only remove it slowly and tediously by attacking from the outside, as all normal pathways to remove damaged tissue have been destroyed, said the company.

AngioDynamics intends to file investigational device exemptions (IDE) with the FDA to pursue additional and more specific tissue indications. The device has been cleared for a general soft tissue ablation indication by the FDA.

For more information: www.angiodynamics.com

Related Content

News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Feature | Cardio-oncology | Dave Fornell

Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat ...

Time May 13, 2016
arrow
News | Oncology Related Products

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy ...

Time May 06, 2016
arrow
Subscribe Now